Pifithrin-β (hydrobromide)

• Description:

  Pifithrin-β hydrobromide (PFT β hydrobromide) is a potent p53 inhibitor with an IC50 of 23 μM.

• Product Name Alternative:

  PFT β (hydrobromide) ; Cyclic Pifithrin-α (hydrobromide)

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Ferroptosis; MDM-2/p53

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Pifithrin-_beta_-hydrobromide.html

• Purity:

  99.97

• Solubility:

  DMSO : 10 mg/mL (ultrasonic)

• Smiles:

  CC1=CC=C(C2=CN3C(SC4=C3CCCC4)=N2)C=C1.Br

• Molecular Formula:

  C16H17BrN2S

• Molecular Weight:

  349.29

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Christodoulou MS, et al. Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. Bioorg Med Chem. 2011 Mar 1;19 (5) :1649-57.|[2]Fernández-Cruz ML, et al. Biological and chemical studies on aryl hydrocarbon receptor induction by the p53 inhibitor pifithrin-α and its condensation productpifithrin-β. Life Sci. 2011 Apr 25;88 (17-18) :774-83.|[3]Da Pozzo E, et al. p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells. ACS Chem Neurosci. 2014 May 21;5 (5) :390-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  BioRxiv. 2025 March 21.|Blood Cells Mol Dis. 2024 Jan:104:102798.|Cancer Cell Int. 2023 Sep 28;23 (1) :221.|Cell Biol Int. 2025 Jul;49 (7) :852-864.|Cell Biol Toxicol. 2023 Oct;39 (5) :2011-2032.|Cell Commun Signal. 2022 Sep 5;20 (1) :96.|Heliyon. 2024 May 19.|Life Sci. 2021 Sep 1:280:119698.|mBio. 2024 Oct 30:e0213724.|Nat Commun. 2025 Feb 25;16 (1) :1774.|FASEB J. 2021 Feb;35 (2) :e21325.|Front Cell Dev Biol. 2020 Jul 29;8:703.|Front Immunol. 2020 Feb 20;8:75.|Front Mol Biosci. 2021 Aug 19;8:697457.|Int J Mol Med. 2021 Jul;48 (1) :122.|Int J Mol Sci. 2023 Jul 17;24 (14) :11554.|iScience. 2024 Jun 4;27 (7) :110144.|J Virol. 2025 Aug 29:e0052925.|PLoS One. 2018 Sep 20;13 (9) :e0203833. |Sci Rep. 2025 Sep 29;15 (1) :33534.

• CAS Number:

  [511296-88-1]